The Joint Corp logo

The Joint Corp(JYNT)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$6.94
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for JYNT

11/13/2026: JYNT (1-star) is currently NOT-A-BUY. Pass it for now.

The Joint Corp. is a small-cap healthcare franchisor that operates the nation's largest network of retail chiropractic clinics under a cash-based, membership model. The company's main strengths lie in its asset-light franchisor structure, which delivers high-margin recurring royalties and removes insurance billing friction for everyday consumers. Its primary growth opportunity centers on expanding its clinic footprint across underpenetrated U.S. markets and reacquiring regional developer territories. However, key risks include sensitivity to consumer discretionary spending, recent negative comparable sales trends, and small-cap price volatility. The stock is best suited for value and growth-oriented investors willing to monitor quarterly clinic visit metrics and franchise expansion execution.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitWhile unit expansion provides a long-term growth runway, recent comparable sales headwinds moderate the pace of immediate expansion.
Momentum investorStrong fit while signal remains positiveMomentum is conditional on positive technical breakouts and sustained upward revisions in quarterly earnings and guidance.
Value investorStrong fitThe stock trades at reasonable valuation multiples relative to its asset-light franchisor cash flow generation potential.
Dividend investorWeak fitThe company does not pay dividends, choosing instead to reinvest capital and repurchase shares.
Low-risk investorWeak fitAs a small-cap consumer-discretionary health stock, it experiences share price volatility and sensitivity to economic cycles.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityMedium / highSmall-cap equity status makes the stock susceptible to broader market swings and liquidity fluctuations.
Valuation riskMediumValuation depends heavily on the successful execution of margin-enhancing franchising strategies.
Competition risk (local practitioners and wellness alternatives)MediumLow barriers to entry for local independent practitioners can challenge regional customer acquisition.
Business qualityMedium / highThe capital-light franchisor model provides high operating leverage and strong cash conversion characteristics.
Dividend incomeLow / noneIncome-focused investors receive no dividend yield from holding the common stock.
Execution riskMedium / highManagement must successfully support franchisees and drive new patient visits amidst consumer spending softness.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 95.00M USD
Price to earnings Ratio 31.55
1Y Target Price 9
Price to earnings Ratio 31.55
1Y Target Price 9
Volume (30-day avg) 71.4K shares
Beta 1.16
52 Weeks Range 6.52 - 10.67
Updated Date 11/15/2026
52 Weeks Range 6.52 - 10.67
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) 0.22

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Medical Care Facilities

BUY participation
88.9%
Active BUY / eligible
8 / 9
30-Day BUY Count Change
+6

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Downtrend
PRICE PATH

Downtrend

The stock has experienced a sustained decline in price over recent periods.

Moderately Choppy
PRICE STABILITY

Moderately Choppy

The stock has experienced noticeable price swings while retaining some directional structure.

Analysis of Past Performance

Type Stock
Historic Profit -55.5%
Avg. Invested days 22
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
JYNT receives a 3-star rating, supported by solid company fundamentals. The rating is constrained by soft unit economics, and weak price momentum.

Company Fundamentals

★★★★★
JYNT has solid overall fundamentals (4 stars), with moderate financial health, moderate growth momentum, and solid ownership. In FY2025 versus FY2024, strong earnings growth (+150.2%) is partially offset by soft cash generation (FCF margin 0.6%), moderate revenue growth (+5.2%), soft profitability (net margin 5.3%).

Financial Health Rating

★★★★★
JYNT's financial health is supported by solid cash strength, including free-cash-flow generation (0.6% of revenue). Profitability is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is JYNT's strongest growth driver at +150.2% FY2025 versus FY2024 (strong, 5 stars). By comparison, while revenue growth (+5.2%, moderate) and free-cash-flow growth (-95.9%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 70.3% and approximately 42.6% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 18.56% supports management-shareholder alignment.

Top 5 Institutional Investors

Bandera Partners LLC 28.74%
Skylands Capital, LLC 6.90%
JCP Investment Management, LLC 4.33%
Vanguard Capital Management, LLC 4.07%
Keller Group Invmt Management Inc 2.44%

Unit Economics (Per $1K Revenue)

★★★★★
JYNT generates approximately $796 of gross profit, $-16 of operating income, and $6 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses explain the 2-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 1,366.76%

Quantitative Style Profile

★★★★★
JYNT has a Short Squeeze Candidate profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

Small / Mid Cap RiskShort Squeeze Risk

How Company Makes Money

Business areaWhat it includesRetail investor read
Franchise Royalties & FeesOngoing royalty payments, initial franchise fees, and regional fees collected from independent clinic operators.This is the core profit driver of the pure-play franchise model, providing steady, high-margin recurring cash flows.
Corporate-Operated ClinicsDirect revenue from patient visits and wellness packages at company-owned clinic locations.Serves as a smaller contributor as the company pivots toward an asset-light franchising structure.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date 2026-11-05
When After Market
Estimate 0.11
Actual 0.1

Profitability

Profit Margin 4.81%
Operating Margin (TTM) 6.03%

Management Effectiveness

Return on Assets (TTM) 4.02%
Return on Equity (TTM) 18.55%

Valuation

Trailing PE 31.55
Forward PE 9.72
Enterprise Value 79.48M
Price to Sales(TTM) 1.62
Enterprise Value 79.48M
Price to Sales(TTM) 1.62
Enterprise Value to Revenue 1.35
Enterprise Value to EBITDA 18.29
Shares Outstanding 13.69M
Shares Floating 5.83M
Shares Outstanding 13.69M
Shares Floating 5.83M
Percent Insiders 18.56
Percent Institutions 70.34

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.